Severe dry eye disease (DED) affects the productivity and quality of life of millions of people. Prompted by the prevalence of this chronic condition, many pharmaceutical companies have set out in search of more robust treatments. Solutions have thus far been elusive but, with new advances in regenerative peptide therapy, researchers are poised to provide more reliable and affordable treatment options.
In an article published in The Ophthalmologist, Maria Chen and Haishan Jang discuss BRIM’s novel peptide treatment, BRM421, and explain how this new class of treatment may have the potential to offer patients full relief of all symptoms within the next decade.
The original article was published online at https://theophthalmologist.com on 17th June 2022.